Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Co-SOFT: Cognitive Function in Early Breast Cancer
NCT00659373Phase 3Completed
- Sponsor
- ETOP IBCSG Partners Foundation
- Start
- Dec 2007
- Primary completion
- Dec 2014
- Modality
- Peptides, Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of triptorelin and exemestane in breast cancer (3 arms), sponsored by ETOP IBCSG Partners Foundation. Primary endpoint: Change in Cognitive Function Over 1 Year. Started Dec 2007; status: completed.
02
Drugs
triptorelinexemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00659373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00659373.